
Pulike Biological Engineering, Inc.
SSE:603566.SS
14.73 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,042.561 | 1,252.694 | 1,228.016 | 1,098.568 | 928.512 | 663.195 | 608.059 | 529.895 | 583.102 | 478.138 | 475.69 | 472.082 | 417.526 | 412.625 | 292.354 | 266.434 |
Cost of Revenue
| 405.63 | 488.398 | 457.34 | 379.949 | 331.247 | 257.639 | 200.23 | 167.837 | 167.312 | 130.405 | 119.144 | 124.782 | 120.085 | 127.108 | 83.815 | 73.728 |
Gross Profit
| 636.931 | 764.296 | 770.676 | 718.619 | 597.264 | 405.556 | 407.829 | 362.058 | 415.79 | 347.733 | 356.546 | 347.3 | 297.441 | 285.517 | 208.539 | 192.706 |
Gross Profit Ratio
| 0.611 | 0.61 | 0.628 | 0.654 | 0.643 | 0.612 | 0.671 | 0.683 | 0.713 | 0.727 | 0.75 | 0.736 | 0.712 | 0.692 | 0.713 | 0.723 |
Reseach & Development Expenses
| 106.045 | 107.297 | 90.455 | 85.572 | 114.837 | 90.815 | 73.461 | 6.202 | 58.461 | 41.765 | 36.873 | 32.788 | 26.028 | 0 | 0 | 0 |
General & Administrative Expenses
| 33.97 | 32.844 | 35.959 | 31.618 | 28.62 | 21.429 | 19.009 | 48.937 | 46.344 | 30.269 | 34.135 | 29.911 | 25.862 | 60.155 | 61.492 | 32.986 |
Selling & Marketing Expenses
| 213.354 | 257.455 | 364.702 | 300.039 | 210.997 | 164.596 | 147.113 | 143.262 | 131.038 | 107.411 | 106.873 | 96.706 | 84.989 | 84.726 | 49.827 | 46.048 |
SG&A
| 247.324 | 477.691 | 400.661 | 331.657 | 239.617 | 186.024 | 166.122 | 192.198 | 177.382 | 137.68 | 141.009 | 126.617 | 110.851 | 144.882 | 111.319 | 79.034 |
Other Expenses
| 185.769 | -13.707 | 58.322 | 28.587 | 20.358 | 32.341 | 16.48 | 25.441 | 37.922 | 14.293 | 9.64 | 23.074 | 12.72 | 5.044 | 11.146 | 0.052 |
Operating Expenses
| 539.139 | 571.282 | 549.438 | 445.816 | 374.811 | 309.18 | 281.277 | 272.419 | 250.429 | 199.941 | 197.543 | 175.458 | 150.459 | 148.406 | 113.305 | 80.901 |
Operating Income
| 97.793 | 193.014 | 183.21 | 284.585 | 246.588 | 106.884 | 136.737 | 107.892 | 183.051 | 154.303 | 157.606 | 169.042 | 141.881 | 132.362 | 92.952 | 109.087 |
Operating Income Ratio
| 0.094 | 0.154 | 0.149 | 0.259 | 0.266 | 0.161 | 0.225 | 0.204 | 0.314 | 0.323 | 0.331 | 0.358 | 0.34 | 0.321 | 0.318 | 0.409 |
Total Other Income Expenses Net
| 0.972 | 1.599 | 0.804 | -0.409 | 14.938 | 10.302 | 16.48 | 25.441 | 37.834 | 13.974 | 9.428 | 23.019 | 9.18 | 4.86 | 10.546 | 0.052 |
Income Before Tax
| 98.764 | 194.613 | 184.013 | 284.176 | 260.005 | 117.186 | 153.216 | 133.333 | 220.902 | 168.544 | 167.034 | 192.06 | 151.061 | 137.222 | 103.498 | 109.139 |
Income Before Tax Ratio
| 0.095 | 0.155 | 0.15 | 0.259 | 0.28 | 0.177 | 0.252 | 0.252 | 0.379 | 0.352 | 0.351 | 0.407 | 0.362 | 0.333 | 0.354 | 0.41 |
Income Tax Expense
| 5.958 | 20.095 | 9.9 | 40.039 | 32.261 | 7.94 | 17.602 | 19.147 | 32.9 | 26.801 | 26.777 | 29.198 | 21.848 | 21.846 | 19.508 | 16.38 |
Net Income
| 92.806 | 174.517 | 167.82 | 244.137 | 227.744 | 109.246 | 135.615 | 114.186 | 188.002 | 141.742 | 140.257 | 162.862 | 129.212 | 115.376 | 83.991 | 92.759 |
Net Income Ratio
| 0.089 | 0.139 | 0.137 | 0.222 | 0.245 | 0.165 | 0.223 | 0.215 | 0.322 | 0.296 | 0.295 | 0.345 | 0.309 | 0.28 | 0.287 | 0.348 |
EPS
| 0.27 | 0.5 | 0.54 | 0.78 | 0.72 | 0.34 | 0.42 | 0.36 | 0.59 | 0.49 | 0.59 | 0.68 | 0.54 | 0.48 | 0.35 | 0.39 |
EPS Diluted
| 0.27 | 0.5 | 0.54 | 0.78 | 0.72 | 0.34 | 0.42 | 0.36 | 0.59 | 0.49 | 0.59 | 0.68 | 0.54 | 0.48 | 0.35 | 0.39 |
EBITDA
| 220.568 | 288.265 | 253.291 | 352.244 | 312.813 | 179.987 | 147.197 | 130.651 | 201.427 | 178.598 | 190.001 | 216.804 | 185.862 | 137.111 | 97.246 | 112.993 |
EBITDA Ratio
| 0.212 | 0.23 | 0.206 | 0.321 | 0.337 | 0.271 | 0.242 | 0.247 | 0.345 | 0.374 | 0.399 | 0.459 | 0.445 | 0.332 | 0.333 | 0.424 |